About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

A 65-year-old woman presents to her primary care provider with a chief complaint of "feeling winded" for the last 3 weeks.

today announced poster presentations on two therapeutic candidates: (1) RP04340, a potent and orally available PROTAC compound targeting KRAS G12C/D/V mutants in cancers, and (2) RP05129 ...

Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...

today announced that the company will present three posters related to both of its pipeline programs at the American Thoracic Society (ATS) 2025 International Conference (ATS 2025). ATS 2025 is ...

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that the company will present ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

The abstracts are scheduled to be posted to the AACR Online Program Planner at 4:30 PM ET on Tuesday, March 25. About AACR The American Association for Cancer Research (AACR) is the first and ...

CONCORD, Mass.–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an abstract will be ...

The presentation will include interactive patient case studies, along with efficacy and safety data from two Phase 3 clinical trials. IBSRELA (tenapanor) is a locally acting inhibitor of the ...

IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible ...

Abstract Title: SynKIR-CAR T Cell Advanced Research (STAR)-101 phase 1 clinical trial for patients with advanced mesothelin-expressing ovarian cancer, mesothelioma, or cholangiocarcinoma. The KIR-CAR ...